AG
KURA icon

Aperio Group’s Kura Oncology KURA Stock Holding History

Aperio Group’s Portfolio KURA Stock Details KURA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		$512K Buy
15,684
+3,924
+33% +$138K ﹤0.01% 1955
2020
Q3 		$360K Buy
+11,760
New +$260K ﹤0.01% 1987
2019
Q3 		– Sell
-537
Closed -$11K – 2542
2019
Q2 		$11K Buy
+537
New +$8.91K ﹤0.01% 2773

Other funds holding KURA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FCMI
Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Holocene Advisors
Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return

Aperio Group's KURA Position: Q4 2020 in Review

Aperio Group increased its Kura Oncology (KURA) stake by 33% in Q4 2020, buying an estimated $138K and bringing the position to 15,684 shares worth $512K. The position accounts for ﹤0.01% of the portfolio, ranked #1955.

Aperio Group first reported a position in KURA in Q2 2019 and has held it in 3 quarters since. 199 funds tracked by Wall St. Rank hold KURA as of Q4 2020.

  • Aperio Group held 15,684 shares of Kura Oncology worth $512K as of Q4 2020.
  • Aperio Group bought 3,924 Kura Oncology shares in Q4 2020, an estimated $138K.
  • Kura Oncology made up ﹤0.01% of Aperio Group's portfolio in Q4 2020, its #1955 holding.
  • Aperio Group first reported a position in Kura Oncology in Q2 2019 and has held it in 3 quarters since.
  • 199 funds tracked by Wall St. Rank held Kura Oncology as of Q4 2020.

Based on Aperio Group's 13F filing for Q4 2020, filed 5 Feb 2021.